Total Valuation
NeoGenomics has a market cap or net worth of CHF1.71B. The enterprise value is CHF2.21K.
Market CapCHF1.71B
Enterprise ValueCHF2.21K
Share Statistics
NeoGenomics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders0.82%
Owned by Institutions38.48%
Financial Efficiency
NeoGenomics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -5.07%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-5.07%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee290.93K
Profits Per Employee-43.21K
Employee Count2,500
Asset Turnover0.53
Inventory Turnover15.57
Valuation Ratios
The current PE Ratio of NeoGenomics is ―. NeoGenomics’s PEG ratio is -0.08.
PE Ratio―
PS Ratio0.41
PB Ratio0.36
Price to Fair Value0.36
Price to FCF-13.83
Price to Operating Cash Flow18.74
PEG Ratio-0.08
Income Statement
In the last 12 months, NeoGenomics had revenue of 727.33M and earned -108.03M in profits. Earnings per share was -4.20.
Revenue727.33M
Gross Profit282.54M
Operating Income-66.08M
Pretax Income-110.27M
Net Income-108.03M
EBITDA-38.69M
Earnings Per Share (EPS)-4.20
Cash Flow
In the last 12 months, operating cash flow was 22.05M and capital expenditures -29.40M, giving a free cash flow of -7.36M billion.
Operating Cash Flow22.05M
Free Cash Flow-7.36M
Free Cash Flow per Share-10.00T>
Dividends & Yields
NeoGenomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta6.14
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
NeoGenomics upcoming earnings date is Nov 10, 2026, TBA (Confirmed).
Last Earnings DateJul 28, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
NeoGenomics as a current ratio of 4.26, with Debt / Equity ratio of 57.06%
Current Ratio4.26
Quick Ratio3.94
Debt to Market Cap1.36
Net Debt to EBITDA-8.08
Interest Coverage Ratio-17.61
Taxes
In the past 12 months, NeoGenomics has paid -2.24M in taxes.
Income Tax-2.24M
Effective Tax Rate0.02
Enterprise Valuation
NeoGenomics EV to EBITDA ratio is -15.87, with an EV/FCF ratio of -28.19.
EV to Sales0.84
EV to EBITDA-15.87
EV to Free Cash Flow-28.19
EV to Operating Cash Flow117.39
Balance Sheet
NeoGenomics has CHF145.54M in cash and marketable securities with CHF448.37M in debt, giving a net cash position of -CHF302.83M billion.
Cash & Marketable SecuritiesCHF145.54M
Total DebtCHF448.37M
Net Cash-CHF302.83M
Net Cash Per Share-CHF10.00T>
Tangible Book Value Per ShareCHF1.00
Margins
Gross margin is 42.92%, with operating margin of -9.09%, and net profit margin of -14.85%.
Gross Margin42.92%
Operating Margin-9.09%
Pretax Margin-15.16%
Net Profit Margin-14.85%
EBITDA Margin-5.32%
EBIT Margin-14.64%
Analyst Forecast
The average price target for NeoGenomics is CHF14.41, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF14.41
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―